Sexual Function in Patients with Metastatic Midgut Carcinoid Tumours

ANA van der Horst-Schrivers, E van Ieperen, ANM Wymenga, HM Boezen, WCM Weijmar-Schultz, IP Kema, WG Meijer, W.W. de Herder, PHB Willemse, TP Links, EGE de Vries

Research output: Contribution to journalArticleAcademicpeer-review

16 Citations (Scopus)

Abstract

Background: Sexual dysfunction is a poorly studied aspect of quality of life in patients with midgut carcinoid tumours. We investigated whether carcinoid patients experience sexual problems. Methods: Patients with metastatic midgut carcinoid tumours filled in a validated questionnaire for sexual dysfunction. The prevalence of dysfunction on the subscales arousal, erection, lubrication, orgasm and dyspareunia was compared to a Dutch reference population. Plasma concentration of gonadal hormones, tryptophan and urinary 5-hydroxyindolacetic acid concentrations were measured. Results: 43 patients were studied, 27 men and 16 women. Sexual dysfunction was present in 29.6% of men and 6.3% of women. The prevalence of sexual dysfunction on the different subscales did not differ from the reference population. Patients with a sexual dysfunction had, compared to those without a sexual dysfunction, a longer duration of disease, 95.3 months (range 5.4-314.5) versus 18.6 months (range 0.6-167.9) (p = 0.024), lower plasma tryptophan concentration (+/- SD) of 31.5 +/- 16.1 and 48.9 +/- 14.5 mu mol/l (p = 0.031), and more often used interferon-alpha, 50% of patients versus 10.5% of patients (p = 0.044). Conclusion: Patients with metastatic midgut carcinoid tumours do not experience sexual problems more often than a reference population. Male patients with sexual dysfunction are characterised by more long-standing disease and lower tryptophan concentration. Copyright (c) 2008 S. Karger AG, Basel
Original languageUndefined/Unknown
Pages (from-to)231-236
Number of pages6
JournalNeuroendocrinology
Volume89
Issue number2
DOIs
Publication statusPublished - 2009

Cite this